- Brand names:
- Pharmaceutical Company:
- Condition/Indication:
- Meeting Date: November 2017
- Public Summary Document (PSD) November 2017 PBAC Meeting - PDF
- Public Summary Document (PSD) November 2017 PBAC Meeting - Word
Lanreotide (acromegaly and functional carcinoid tumour) – November 2017
Lanreotide (acromegaly and functional carcinoid tumour): Injection 60 mg (as acetate) in single dose
Last updated
2 March 2018